Chloroquine: Consideration of maximum daily dose (3.5 mg/kg ideal body weight) prevents retinopathy?

Dermatology

Volumn 192, Issue 4, 1996, Pages 382-383

  Ochsendorf, F R ^a   Runne, U ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Chloroquine; Ideal body weight; Retinopathy

Indexed keywords

ANTIRHEUMATIC AGENT; CHLOROQUINE; MEPACRINE;

BODY WEIGHT; DRUG WITHDRAWAL; ELECTRORETINOGRAPHY; HUMAN; LETTER; PRIORITY JOURNAL; RETINOPATHY; SKIN LUPUS ERYTHEMATOSUS;

BODY WEIGHT; CHLOROQUINE; HUMANS; LUPUS ERYTHEMATOSUS, DISCOID; RETINAL DISEASES;

EID: 0029950012     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000246421     Document Type: Article

References (5)

1. Lipskcr D, Picttc JC, Cacoub P. Godeau P. Frances C: Chloroquine-quinacrine association in resistant cutaneous lupus. Dermatology 1995; 190:257-258.
2. Cox NH. Paterson WD: Ocular toxicity of antimalarials in dermatology: A survey of current practice. Br J Dermatol 1994;131:878-882.
3. Maksymowych W. Russell AS: Antimalarials in rheumatology: Efficacy and safety. Semin Arthritis Rheum 1987:16:206-221.
4. Ochsendorf FR. Runnc U. Gocrz G. Zrenner F.: Chloroquin-Retinopalhic: Durch imlividuellc Tagesdosis vermeidbar. Dtsch Med Wochenschr 1993:118:1895-1899.
5. Mackenzie AH: Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials. Am J Med 1983:75(suppl):40-45